What top creators are saying about Biohaven Ltd.(BHVN)

Host likes Biohaven, readouts coming soon, pre-catalyst pharma play with upcoming clinical data.

Regarded as a strong long-term 'management pick' within the biotech sector.

Noted for having good management within the biotech/rare disease strategy.

Described as a 'high-quality company with smart management and good assets,' indicating a generally positive and bullish view.

The speaker is long but calls its performance 'dog poopoo'. The slight bullishness comes from insider buying in a secondary offering, which is seen as a positive sign that the 'worst is over'.

It is the speaker's second biggest long position due to strong insider confidence, as major shareholders and board members participated heavily in a recent deal.

The stock price fell after the company announced a $150 million stock sale, which dilutes the ownership stake for existing shareholders.

The speaker is long, believing the company has strong support from Wall Street ("a lot of fans") and easy access to capital.

Long-term bullish, actively buying more shares based on the strength of the CEO, despite short-term headwinds from an FDA Complete Response Letter (CRL) and an expected financing.

The speaker is very bullish, stating it is his 'biggest position' and is holding it with strong conviction through a market downturn.

Speaker has gone 'all in' with an 80% position, viewing the stock as unfairly punished after an expected FDA rejection. Believes the market overreacted and long-term supporters will cause the price to recover.

A high-risk, high-reward biotech stock centered around a near-term FDA decision. The speaker suggests it could be a 'buy a little here' situation, viewing it as a good long-term hold due to strong management, even if the lead drug fails.

Listed as one of the biotech/pharma companies the speaker holds positive views on and/or has positions in.

Held as a long position and bullish bet in the speaker's personal trading account.